BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

XERIS PHARMACEUTICALS, INC. — Lobbying — Receipts Report

LD-2 disclosure · Registration - Amendment

XERIS PHARMACEUTICALS, INC.

via THE CONAFAY GROUP, LLC

3rd Quarter (July 1 - Sep 30) · 2022Posted Oct 19, 2022Filing document ↗LDA record ↗

Coverage · Registration amendment — updates registrant or client details already on file; not a periodic activity report.

Client

Name: XERIS PHARMACEUTICALS, INC.
Description: Pharmaceutical company
Location: Illinois · United States of America

Registrant

Firm: THE CONAFAY GROUP, LLC
Description: Life Sciences Consulting Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medical/Disease Research/Clinical Labs
Support for Glucagon rescue therapy
LobbyistsJULIE P. PAWELCZYK · NORA SANZO

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.